Thread by @VietHeartPA

TRANSFORM-HF

What do we really know about efficacy of furosemide vs torsemide?

I am sure @robmentz and team have something to say about this 👊🏾

pubmed.ncbi.nlm.nih.gov/33714745/

#AHA #LBCT @AHAScience @noshreza

Chlorthalidone versus HCTZ - pragmatic emr study by @Areefishani et al. After #SPRINTTrial I use chlorthalidone. What’s the evidence?

pubmed.ncbi.nlm.nih.gov/35390512/

#AHA #LBCT @AHAScience @noshreza

PPAR-alpha (e.g., fenofibrate, permafibrate) - Are triglycerides as a target out for CV event reduction, or just this mechanism?

pubmed.ncbi.nlm.nih.gov/30342298/ @APradhanBrigham to present 👊🏾

#AHA #LBCT @AHAScience @noshreza

#CRISPR tech is a potential game changer, for TTR and other diseases. Looking fwd to Dr Gillmore’s presentation. #amyloidosis

pubmed.ncbi.nlm.nih.gov/34215024/

#AHA #LBCT @AHAScience @noshreza

#Coachtrial for acute #HF presenting at the ED. Does risk stratification and rapid amb care improve outcomes?

pubmed.ncbi.nlm.nih.gov/33984316/

#AHA22 #LBCT @AHAScience @noshreza

Will patient reported health quality impact patient outcomes and clinical decision making in #HF?

clinicaltrials.gov/ct2/show/NCT04…

#AHA22 #LBCT @AHAScience @noshreza

Are we ready for #CRISPR? Looking forward to #LBCT this afternoon.

#aha22 @AHAScience @noshreza #cardiacamyloidosis

nejm.org/doi/full/10.10…

https://twitter.com/vietheartpa/status/1588539346768265219

#HF #LBCT this afternoon.

#aha22 @AHAScience @noshreza

sciencedirect.com/science/articl…

https://twitter.com/vietheartpa/status/1588540249474727936